FTC 'Ready' To Go After Abusive Citizen Petitions; Allergan Wants 'Substantive' FDA Responses

US FDA draft guidance on citizen petitions elicits comments of support, including call to exclude brand manufacturer petitions except in urgent situations.

Vertical stack of multicolor office binders with Statements tags 3D rendering

The US Federal Trade Commission told FDA it is ready to help the agency halt citizen petitions that are intended to delay approval of generics or biosimilars.

In October, the agency issued revised draft guidance on citizen petitions saying that if it determines a petition has been...